IDO rout: Pivotal trials with Bristol-Myers, Merck and AstraZeneca dumped in wake of Incyte's PhIII implosion
The IDO R&D pipeline is in danger of being exterminated.
In the wake of a pivotal failure of Incyte’s $INCY lead IDO drug epacadostat, Bristol-Myers Squibb $BMY became the third player forced to retrench in that immuno-oncology field, dropping three late-stage studies of a rival drug it bagged in a $1.25 billion buyout. But that was just the start of a rout.
Incyte reported this morning that its wide-ranging collaborations with Big Pharma players are coming undone. In their Q1 announcement, echoing the failure of ECHO-301, the company noted:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.